COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Protocol No
IIT-DHAKAL-IMPEDE-SGZ-12356
Principal Investigator
Binod Dhakal
Phase
II
Summary
The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Pomalidomide, Elotuzumab, and Dexamethasone for the treatment of multiple myeloma. Researchers would like to study the possible side effects associated with this new study drug combination. They also want to see if the new study drug combination is better at treating multiple myeloma compared to other standard of care treatment options.
Description
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL